# A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

> **NCT03525548** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 113 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-445/TEZ/IVA
- **DRUG:** TEZ/IVA
- **DRUG:** IVA
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03525548
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-03
- **Primary completion:** 2018-12-28
- **Final completion:** 2018-12-28
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525548, "A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03525548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*